• Tenax Therapeutics posted a presentation detailing Phase 3 LEVEL trial results for TNX-103 (levosimendan) in PH-HFpEF.
• Primary endpoint missed: 6-minute walk distance improved 14 m on TNX-103 vs 10.4 m on placebo; treatment difference 3.5 m (p=0.63).
• Prespecified subgroup below median baseline 6MWD (<333 m) showed a 26.3 m placebo-adjusted improvement; 95% CI 6.0 to 46.7.
• NT-proBNP fell 49% in the study; RVSP declined 3.5 mmHg, supporting a bi-ventricular hemodynamic effect.
• Company framed the neutral topline result as a patient-selection issue; plans to reshape LEVEL-2 to enrich for more impaired patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.